Cancer, HER2-expressing cancers, Metastatic breast cancer, Metastatic colorectal cancer
VIRVir BiotechnologyCatalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for VIR-5818 + Pembrolizumab in Cancer, HER2-expressing cancers, Metastatic breast cancer, Metastatic colorectal cancer. The expected timing is based on the latest available company guidance and may change.
11/7/24- Share initial clinical data in Q1 2025. 1/8/25- Announced safety & efficacy data. Currently evaluating Q3W dosing. 11/05/25:- VIR-5818, a HER2-targeting PRO-XTEN dual-masked T-cell engager, continues in a Phase 1 dose escalation study with pembrolizumab across multiple tumor types, including metastatic colorectal cancer, with no new data or timing disclosed. 01/12/26:- VIR-5818 Phase 1 dose escalation response data in H2 2026; trials continue enrolling HER2-expressing solid tumors. 02/23/26:- Ph1 VIR-5818/pembrolizumab dose-escalation ongoing; response data expected in H2 2026. 05/06/26:- Phase 1 VIR-5818/pembrolizumab dose-escalation ongoing; response data still expected in H2 2026. 08/05/26:- Phase 1 VIR-5818 data timing reiterated for H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.